Urinary tract infections in immunocompromised patients

Purpose of review Urinary tract infections (UTIs) are a major source of morbidity in immunocompromised patients, including transplant recipients, individuals with hematologic malignancies, people living with HIV, and those receiving immunosuppressive therapies. This review provides a synthesis of recent evidence, highlighting challenges in diagnosis, management, and antimicrobial resistance in these high-risk populations. Recent findings Recent literature highlights the high burden of UTIs among immunocompromised patients. These infections are often caused by multidrug-resistant pathogens. Across these groups, common risk factors include immunosuppression, diabetes, urologic instrumentation, and catheterization. Diagnostic uncertainty – particularly distinguishing true infection from asymptomatic bacteriuria – frequently leads to overtreatment. Emerging stewardship tools, such as reflex urinalysis protocols and electronic phenotyping of antimicrobials (e.g. the use of the ‘Acute Urinary Antibiotics’ labelling), show promise for reducing inappropriate antibiotic use in outpatient settings. Summary UTIs in immunocompromised patients are increasingly complex due to atypical presentations and resistant pathogens. Clinical care must prioritize accurate diagnosis, judicious use of antibiotics, and implementation of stewardship interventions. Further research is needed to validate risk-based diagnostic tools and expand outpatient stewardship infrastructure in transplant and oncology settings.